Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform

医学 2型糖尿病 肾脏疾病 内科学 糖尿病 队列 入射(几何) 高钾血症 人口 队列研究 内分泌学 环境卫生 物理 光学
作者
Atsuhisa Sato,Daloha Rodríguez-Molina,Kanae Yoshikawa-Ryan,Satoshi Yamashita,Suguru Okami,Fangfang Liu,Alfredo E. Farjat,Nikolaus G. Oberprieler,Csaba P. Kövesdy,Keizo Kanasaki,David Vizcaya
出处
期刊:Journal of Clinical Medicine [MDPI AG]
卷期号:13 (17): 5107-5107
标识
DOI:10.3390/jcm13175107
摘要

Background: In the phase 3 clinical trials FIGARO-DKD and FIDELIO-DKD, finerenone reduced the risk of cardiovascular and kidney events among people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Evidence regarding finerenone use in real-world settings is limited. Methods: A retrospective cohort study (NCT06278207) using two Japanese nationwide hospital-based databases provided by Medical Data Vision (MDV) and Real World Data Co., Ltd. (RWD Co., Kyoto Japan), converted to the OMOP common data model, was conducted. Persons with CKD and T2D initiating finerenone from 1 July 2021, to 30 August 2023, were included. Baseline characteristics were described. The occurrence of hyperkalemia after finerenone initiation was assessed. Results: 1029 new users of finerenone were included (967 from MDV and 62 from RWD Co.). Mean age was 69.5 and 72.4 years with 27.3% and 27.4% being female in the MDV and RWD Co. databases, respectively. Hypertension (92 and 95%), hyperlipidemia (59 and 71%), and congestive heart failure (60 and 66%) were commonly observed comorbidities. At baseline, 80% of persons were prescribed angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers. Sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists were prescribed in 72% and 30% of the study population, respectively. The incidence proportions of hyperkalemia were 2.16 and 2.70 per 100 persons in the MDV and RWD Co. databases, respectively. There were no hospitalizations associated with hyperkalemia observed in either of the two datasets. Conclusions: For the first time, we report the largest current evidence on the clinical use of finerenone in real-world settings early after the drug authorization in Japan. This early evidence from clinical practice suggests that finerenone is used across comorbidities and comedications.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
江小霜发布了新的文献求助30
刚刚
星辰大海应助bofu采纳,获得30
1秒前
鹿靡完成签到 ,获得积分10
2秒前
2秒前
wenwen完成签到,获得积分10
2秒前
zhangling发布了新的文献求助10
3秒前
今天也为文献啄米完成签到,获得积分10
4秒前
十三完成签到,获得积分10
5秒前
Hanson发布了新的文献求助10
5秒前
东海虞明完成签到,获得积分10
5秒前
顾矜应助难得糊涂zq采纳,获得10
6秒前
9秒前
9秒前
Hello应助bofu采纳,获得10
9秒前
10秒前
10秒前
10秒前
梓泽丘墟应助狂野东蒽采纳,获得10
10秒前
隐形曼青应助纪代桃采纳,获得10
12秒前
Owen应助zhangling采纳,获得10
13秒前
14秒前
14秒前
yqy-123完成签到,获得积分10
14秒前
俊逸尔风完成签到 ,获得积分10
15秒前
15秒前
15秒前
pearlwh1227发布了新的文献求助10
16秒前
AREA4发布了新的文献求助10
16秒前
17秒前
楼山柳发布了新的文献求助10
17秒前
NICOHUK发布了新的文献求助10
17秒前
17秒前
18秒前
希望天下0贩的0应助bofu采纳,获得10
18秒前
忧虑的靖巧完成签到 ,获得积分10
18秒前
冷傲星月完成签到,获得积分10
19秒前
19秒前
19秒前
19秒前
19秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3160703
求助须知:如何正确求助?哪些是违规求助? 2811860
关于积分的说明 7893601
捐赠科研通 2470679
什么是DOI,文献DOI怎么找? 1315754
科研通“疑难数据库(出版商)”最低求助积分说明 630993
版权声明 602053